Press Room
News
-
26 May 2010 -
Funxional Therapeutics raises 10 million Euros in a private Series B financing round to fund the initial Phase II clinical studies of FX125L in inflammation.
- FXT Series B Financing Press Release PDF
-
8 January 2010 -
Funxional Therapeutics Announces successful completion of the Phase I Programme of its Novel Anti-inflammatory Small Molecule, FX125L
- FXT03 Press Release PDF
-
-
-
Events
Please check back for future event information.